Christoph S.
- Country
- Germany
- Department
- Klinik für Innere Medizin, Hämatologie
Research Overview
- Phase II Open‑Label Study of Cevostamab Combined with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Post‑BCMA CAR‑T Therapy
- Evaluation of Daratumumab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone for Transplant-Ineligible Multiple Myeloma Patients
- Phase 3 Randomized Trial of Talquetamab, Daratumumab, and Pomalidomide Combinations in Relapsed/Refractory Multiple Myeloma Post-One Therapy Line
Data & Insights
Has run more than one trial at 60 of 171 partner sites.
Specializations
Multiple Myeloma Treatment
This investigator specializes in developing innovative therapeutic approaches for multiple myeloma, with particular emphasis on both newly diagnosed and relapsed/refractory cases.
- Novel Combination Therapies
- Stem Cell Transplantation Protocols
- Immunotherapy Applications
Their work encompasses evaluating cutting-edge treatments including monoclonal antibodies and CAR-T cell therapy approaches.
Hematologic Malignancies
The investigator focuses on advanced therapeutic strategies for blood disorders, including specialized research in myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia.
- Treatment-Resistant Disease Management
- Novel Drug Combinations
- Targeted Therapy Development
Their expertise extends to developing protocols for allogeneic blood cell transplantation in high-risk patients.
Drug Development and Clinical Innovation
The investigator leads research in therapeutic advancement through evaluation of novel drug formulations and delivery methods.
- Subcutaneous Drug Administration
- Maintenance Therapy Optimization
- Response Assessment Protocols
Their work includes investigating minimal residual disease monitoring and developing new treatment sequences.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.